Abstract
Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Current Enzyme Inhibition
Title: Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Volume: 2 Issue: 1
Author(s): John D. Imig and Xueying Zhao
Affiliation:
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Abstract: Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Export Options
About this article
Cite this article as:
Imig D. John and Zhao Xueying, Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease, Current Enzyme Inhibition 2006; 2 (1) . https://dx.doi.org/10.2174/157340806775473544
DOI https://dx.doi.org/10.2174/157340806775473544 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Urinary Exosomal Lipidomics Reveals Markers for Diabetic Nephropathy
Current Metabolomics Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Gymnema sylvestre R. Br., an Indian Medicinal Herb: Traditional Uses, Chemical Composition, and Biological Activity
Current Pharmaceutical Biotechnology Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications
Current Diabetes Reviews Update on AKI Biomarker Patents
Current Biomarkers (Discontinued) Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]
Current Vascular Pharmacology The Role of Plant-Derived Compounds in Managing Diabetes Mellitus: A Review of Literature from 2014 To 2019
Current Medicinal Chemistry A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Existing and Emerging Therapies for Acute Gout and Long-Term Urate Lowering
Current Rheumatology Reviews EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry MRI findings and renal function in patients on lithium therapy
Current Drug Safety